Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 1/20 | 0.51 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.50 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20010222 | 0.89 | ADORA2A (0.48) | ADORA2AADORA2BADORA3 | |
| SCHEMBL20009993 | 0.88 | ADORA2A (0.49) | ADORA2AADORA2BADORA3 | |
| SCHEMBL20010051 | 0.87 | ADORA2A (0.40) | DNMT1DNMT3BADORA2AADORA2BRNASEL | |
| SCHEMBL20010094 | 0.85 | ADORA2A (0.54) | ADORA2AADORA2BADORA3 | |
| SCHEMBL25619503 | 0.84 | DNMT1 (0.56) | DNMT1DNMT3BADORA2AADORA2BRNASEL | |
| SCHEMBL25619482 | 0.84 | DNMT1 (0.56) | DNMT1DNMT3BADORA2AADORA2BRNASEL | |
| SCHEMBL20010053 | 0.81 | ADORA2A (0.38) | ADORA2AADORA2BADORA3 | |
| SCHEMBL20010054 | 0.81 | ADORA2A (0.38) | ADORA2AADORA2BADORA3 | |
| SCHEMBL18852342 | 0.80 | DNMT1 (0.57) | DNMT1DNMT3BADORA2AADORA2BRNASEL | |
| SCHEMBL14928484 | 0.80 | DNMT1 (0.57) | DNMT1DNMT3BADORA2AADORA2BRNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNATX, INC. | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086807-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | DNMT1 488/4885DNMT3B 262/4885ADORA2A 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.